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Fatty acidMitochondrial dysfunction in skeletal muscle has been suggested to underlie the development of insulin
resistance and type 2 diabetes mellitus. Reduced mitochondrial capacity will contribute to the accumulation
of lipid intermediates, desensitizing insulin signaling and leading to insulin resistance. Why mitochondrial
function is reduced in the (pre-)diabetic state is, however, so far unknown. Although it is tempting to suggest
that skeletal muscle insulin resistance may result from an inherited or acquired reduction in mitochondrial
function in the pre-diabetic state, it cannot be excluded that mitochondrial dysfunction may in fact be the
consequence of the insulin-resistant/diabetic state. Lipotoxicity, the deleterious effects of accumulating fatty
acids in skeletal muscle cells, may lie at the basis of mitochondrial dysfunction: next to producing energy,
mitochondria are also the major source of reactive oxygen species (ROS). Fatty acids accumulating in the
vicinity of mitochondria are vulnerable to ROS-induced lipid peroxidation. Subsequently, these lipid
peroxides could have lipotoxic effects on mtDNA, RNA and proteins of the mitochondrial machinery, leading
to mitochondrial dysfunction. Indeed, increased lipid peroxidation has been reported in insulin resistant
skeletal muscle and the mitochondrial uncoupling protein-3, which has been suggested to prevent lipid-
induced mitochondrial damage, is reduced in subjects with an impaired glucose tolerance and in type 2
diabetic patients. These findings support the hypothesis that fat accumulation in skeletal muscle may
precede the reduction in mitochondrial function that is observed in type 2 diabetes mellitus.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The prevalence of type 2 diabetes mellitus is increasing dramat-
ically and reaches epidemic proportions worldwide. The WHO
predicts that 350–400 million people will suffer from type 2 diabetes
in the year 2030 [1]. The increase in the prevalence of type 2 diabetes
mellitus is a reflection of the alarming (and still increasing) number of
people that are overweight. Environmental factors like consumption
of high-fat and/or energy-rich diets and low levels of physical activity
are likely to underlie this high prevalence of obesity.
In obesity, the accumulation of excessive fat in non-adipose tissues
such as liver, heart and muscle (=ectopic fat accumulation)
negatively impacts health. In sedentary humans, fat accumulation in
skeletal muscle (and liver) strongly associates with insulin resistance,
predisposing to the development of type 2 diabetes mellitus [2].
Indeed, both type 2 diabetic patients [3] and their diabetes-prone
first-degree relatives [4,5] are characterized by high levels of
intramyocellular lipids (IMCL) and muscular insulin resistance. On
the contrary, endurance-trained athletes, who are among the most31 43 3670976.
rauwen).
ll rights reserved.insulin-sensitive subjects, are also characterized by high IMCL levels
[3,6], indicating that high IMCL levels per se do not necessarily lead to
insulin resistance. We (and others) have previously suggested that
the increase in IMCL following endurance training serves to match the
training-induced increase in oxidative capacity and reliance on fat as a
substrate during exercise [6]. In contrast, the increase in IMCL under
obesogenic/diabetogenic conditions is due to a surplus of fat
availability (high plasma FFA levels, high-fat diets) and is NOT
matched by improved oxidative capacity. Under the latter conditions
the intermediates of IMCL metabolism such as fatty acyl-CoA,
diacylglycerol and ceramides will also accumulate and especially
these intermediates impede cellular insulin signalling (for review see:
[7,8]). The above concept predicts that a low oxidative capacity–
combined with high IMCL levels–predisposes to the development of
insulin resistance. Indeed, (pre-)diabetic subjects are characterized by
low oxidative capacity. In fact, in the recent 5–7 years, skeletal muscle
mitochondrial dysfunction has been implicated in the aetiology of
insulin resistance and type 2 diabetes mellitus.
2. Mitochondrial dysfunction and type 2 diabetes
In 2002, Kelley et al. [9] were one of the first to raise the issue of
mitochondrial dysfunction in type 2 diabetes mellitus. Thus, the
267P. Schrauwen et al. / Biochimica et Biophysica Acta 1801 (2010) 266–271authors observed that mitochondrial morphology was altered in type
2 diabetic patients, including a reduction in mitochondrial area size
and an elevated number of damaged mitochondria. Mitochondrial
surface area was found to correlate positively with insulin stimulated
glucose disposal [9]. In addition, they reported that the activity of
rotenone sensitive NADH:O2 oxidoreductase, reflecting the overall
activity of the respiratory chain, and citrate synthase were reduced in
type 2 diabetic patients [9]. One year later, the interest for
mitochondrial aberrations in the development of type 2 diabetes
mellitus exploded when two independent studies were simulta-
neously published in different high-impact journals. These studies
showed a coordinated reduction in the expression of genes encoding
key enzymes in oxidative mitochondrial metabolism in (first-degree
relatives of) diabetic patients [10,11]. Using micro-arrays it was
shown that the mRNA expression of genes that encode for proteins
involved in mitochondrial metabolism were mildly, but consistently
lower expressed in muscle of type 2 diabetic patients and/or first-
degree relatives of type 2 diabetic patients. Many of these genes are
under the control of the transcription co-activator PGC1α, which was
also found to be reduced in type 2 diabetic patients [10,11] and in
family history-positive non-diabetic subjects [10]. This reduction in
PGC1α gene expression has been confirmed by others [12,13].
However, it should be noted that changes in PGC1αmRNA expression
should be interpreted with caution, as PGC1α has been shown to be
regulated by post-translational modification and thus mRNA levels do
not necessarily reflect activity of the protein [14].
Following these indications for aberrations in mitochondrial
function in the diabetic state, several authors have applied non-
invasive magnetic resonance spectroscopy (MRS) for the in vivo
determination of skeletal muscle mitochondrial function. One way in
doing so is by determining the rate of unidirectional flux through ATP
synthase (ATP synthetic flux, fATPase) in the non-exercising state.
This can be done by using the magnetization (saturation) transfer
method in which the signal derived from ATP is temporarily
suppressed and subsequent changes in the steady state MR signal of
free phosphate are quantified to calculate unidirectional ATP
synthesis rate. Simultaneously, flux through the tricarboxylic acid
(TCA or Krebs) cycle can be determined non-invasively by carbon-13
(13C) MRS. Using this 13C-and 31P-MRS method, Petersen et al. [15]
reported that muscular fATPase and oxidative metabolism (TCA cycle
flux) were decreased by ∼40% in elderly subjects when compared to
BMI-matched young, healthy subjects without a family history of type
2 diabetes subjects. The older volunteers were also characterized by
elevated levels of muscular fat and by muscular insulin resistance,
suggesting that an age-associated decline in mitochondrial function
might contribute to the development of insulin resistance. Using
similar methodology, the same research group later found that IMCL
and fATPase were, respectively, 80% higher and 30% lower in lean, but
insulin-resistant offspring of type 2 diabetic patients who were
matched for age, BMI and habitual physical activity with insulin
sensitive healthy subjects [16]. Consistent with this finding, Szen-
droedi et al. [17] recently reported that in vivo ATP synthesis rate was
decreased by 27% in non-obese metabolically well-controlled type 2
diabetic patients compared to young, healthy control subjects.
We have applied an alternative 31P-MRS method to investigate in
vivo mitochondrial function by measuring the kinetics of phospho-
creatine (PCr) resynthesis during recovery from submaximal exercise
[18,19]. Importantly, and in contrast to the magnetization saturation
transfer method, the PCR-recovery methodology assesses mitochon-
drial function under conditions of increasedmetabolic demand.When
we then compared in vivo mitochondrial function in type 2 diabetic
patients versus normoglycemic, obese control subjects matched for
BMI [20], we showed that in vivo mitochondrial function was
compromised by ∼45% in type 2 diabetic patients [20]. Interestingly
however, IMCL content was similar between the groups, suggesting
that impaired mitochondrial function may be a more importantdeterminant of diabetes than IMCL levels per se. Recently, we have
confirmed this observation of reduced in vivo mitochondrial function
in type 2 diabetic patients and in addition showed that also first-
degree relatives of type 2 diabetic patients (FDR) had a similar
reduction in mitochondrial function [21]. Again, in these subjects that
were all matched for BMI, no differences in IMCL content were
observed between healthy obese, FDR and type 2 diabetic subjects
[21]. Taken together, these studies are consistent in showing a
reduction in in vivo mitochondrial function in insulin resistant
subjects and/or type 2 diabetic patients.
In vivo mitochondrial function is not only determined by intrinsic
mitochondrial function, but also by mitochondrial content and even
substrate supply to the skeletal muscle. To address if themitochondria
per se have a reduced capacity, ex vivo studies are needed. Three
studies have been published that examined ex vivo mitochondrial
function (to determine “intrinsicmitochondrial function”) using high-
resolution respirometry in muscle of type 2 diabetic patients. Boushel
et al. [22] found that ADP-stimulated state 3 respiration, both with
substrates for complex I and/or complex II, was normal in
permeabilized skinned muscle fibers from type 2 diabetic patients,
when corrected for mitochondrial density. In contrast, Mogensen et al.
[23] reported that maximal ADP-stimulated respiration (state 3) with
pyruvate as a substrate and respiration through the electron transport
chain (ETC) was reduced in mitochondria isolated from diabetic
patients. However, both studies did not determine in vivo mitochon-
drial function. In our study outlined above, in which we showed
reduced in vivomitochondrial function in type 2 diabetic patients and
first-degree relatives [21], we also determined ex vivo mitochondrial
function. We showed that a lower ex vivo (ADP-stimulated and
maximally uncoupled) mitochondrial respiration underlies the
reduction in in vivo mitochondrial function. Interestingly, we found
similar tendencies of reduced intrinsic mitochondrial function in first-
degree relatives of type 2 diabetic patients. These findings were not
explained by reduced mitochondrial density, as both CS and mtDNA
copy number were similar in all groups [21].
Taken together, there is indeed evidence for abnormalities in in
vivo and intrinsic mitochondrial function in the (pre-)diabetic state.
This led others to formulate the hypothesis that this (acquired or
inherited) reduced mitochondrial function in the pre-diabetic state
leads to accumulation of fat in muscle, thereby contributing to the
development of insulin resistance [15,16].
3. Mitochondrial lipotoxicity
Although the above-mentioned hypothesis sounds firm, there are
also data suggesting that mitochondrial dysfunction is not required
for the development of type 2 diabetes mellitus or even the
accumulation of muscular fat. First of all, several studies with
genetically manipulated mouse models have suggested that a
reduction in mitochondrial oxidative capacity in fact improves insulin
sensitivity. Thus, Pospisilik et al. [24] generated mice with a deletion
of the mitochondrial flavoprotein apoptosis-inducing factor (AIF)
resulting in dysfunction of the oxidative phosphorylation. In contrast
to what was expected, these mice had improved glucose tolerance
and were protected from high-fat diet induced insulin resistance.
Similarly, Wredenberg et al. [25] reported that mice with a skeletal
muscle-specific deletion of mitochondrial transcription factor A
(Tfam), resulting in marked reduction in oxidative phosphorylation
capacity, were normal insulin sensitive and had an increased
peripheral glucose uptake upon a glucose tolerance test. Also,
PPARα ablation in muscle–thereby decreasing fat oxidative capaci-
ty–resulted in improvements in glucose homeostasis, whereas PPARα
overexpression–improving oxidative capacity–had the opposite
effects [26]. Together, these studies in genetically modified animals
have suggested that in fact an ablation of mitochondrial oxidative
capacity improves instead of impairs glucose homeostasis. Although
Fig. 1. Simplified schematic presentation of the “lipotoxicity hypothesis.” In
diabetogenic conditions (obesity, high-fat diets, low physical activity), fatty acids will
accumulate in muscle cells in the vicinity of mitochondria. These fatty acids can exert
lipotoxic effects on mitochondrial function, thereby further aggregating oxidative
capacity and muscle fat accumulation.
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mitochondrial dysfunction in the development of muscular insulin
resistance, such an interpretation would be an oversimplification. It
has been known for decades that in muscle (and other tissues)
substrate competition between glucose and fatty acids determines the
ultimate mix of fuel used for ATP production, as for example elegantly
postulated in the Randle hypothesis [27]. A forced reduction/
induction of the capacity to burn one substrate, will lead to a
compensatory increase in the other substrate. The results of the
above-mentioned mouse models can be explained by such substrate
competition, as was also discussed by Finck et al. [26]. In fact, blockers
of fat oxidation have previously been used for the treatment of type 2
diabetes. For example, we have previously shown that etomoxir,
which reduces fat oxidation via inhibition of CPT1, indeed results in a
reduction in fat oxidation but also an improvement in glucose
metabolism, including enhanced basal GLUT4 translocation and
lowering of plasma glucose levels [28]. In addition, part of the results
in the animal studies is most likely explained by activation of the
enzyme AMPK, a sensor of the energy status of the cell. Most likely,
ablation of components of the oxidative phosphorylation system
resulting in reduced mitochondrial function, will activate AMPK and
thereby improve GLUT4 translocation and glucose uptake. For these
reasons, the value of studies genetically disturbing oxidative phos-
phorylation for understanding the role of mitochondrial dysfunction
in the development of type 2 diabetes mellitus is limited and
interpretation of these studies should be done with more caution.
However, next to these mice studies, other observations have been
reported that question the hypothesis that mitochondrial dysfunction
underlies the development of type 2 diabetes mellitus or muscular fat
accumulation. Thus, the acute elevation of circulating plasma fatty
acids results in marked muscular fat accumulation and insulin
resistance [29]—and importantly, these effects can also be induced
in healthy or even endurance trained subjects, indicating indepen-
dence of mitochondrial dysfunction. Furthermore, short-term con-
sumption of high-fat diets (7 days) increased IMCL levels by 50% in
lean, young and healthy subjects [30], whereas it has been shown that
human subjects are capable of adjusting their fat oxidation to high-fat
intake within this time-frame [31]. Moreover, it is important to realize
that the suggestion that mitochondrial dysfunction precedes the
development of insulin resistance originates from cross-sectional
human studies in which a reducedmitochondrial function was always
accompanied by increased/high muscular lipid content. For example,
in offspring of type 2 diabetic patients a 30% reduction in
mitochondrial function was already accompanied by a ∼80% increase
in IMCL content [16]. In our study, IMCL levels were comparable
between diabetic patients, FDR and controls [21], despite marked
differences in mitochondrial function. Finally, as recently addressed
by Holloszy [32] it can be questioned if a 20–40% reduction in in vivo
mitochondrial function or mitochondrial content as has been
reported, would affect substrate oxidation and thereby fat accumu-
lation in the resting state, given that mitochondria work at a very low
fraction of their maximal capacity at rest.
Therefore, the question “cause or consequence” remains unan-
swered, and it is equally well possible that mitochondrial dysfunction
in these studies is in fact the consequence of high concentrations of fat
in the muscle cells: mitochondrial lipotoxicity (Fig. 1). Recent studies
support this view: In a study where Szendroedi et al. [17] reported a
27% decrease in basal ATP synthesis rates in type 2 diabetic patients,
they also found that plasma FFA levels correlated negatively with
mitochondrial function, suggesting that lipid oversupply to the
muscle may deteriorate mitochondrial function. Furthermore, the
reduced PGC1α gene expression that has been reported in insulin
resistant subjects might also be the consequence of elevated plasma
and/or muscular fatty acid levels. Thus, we and others recently
showed that the acute elevation of plasma fatty acids, leading to
accumulation of intramuscular lipids, was accompanied by down-regulation of the transcriptional co-activator PGC1α, as well as other
genes involved in mitochondrial metabolism [33,34]. Also, the
observed aberrations in mitochondrial morphology, i.e. smaller but
most of all damaged mitochondria that were reported in type 2
diabetic patients [9] fit with the concept of lipotoxicity in skeletal
muscle leading to mitochondrial dysfunction.
4. High-fat diet induced mitochondrial dysfunction
Several studies have tested the concept that in fact muscular fat
accumulation may precede the development of mitochondrial
dysfunction. Most of these studies have used high-fat diets to
manipulate the IMCL content and assess the impact on mitochon-
drial function. Sparks et al. [35] were the first to show that feeding
C57Bl/6J mice a high-fat diet for 3 weeks resulted in the down
regulation of genes involved in mitochondrial oxidative phosphor-
ylation [35]. In addition, these authors showed that in humans
consumption of a high-fat diet (50 En% fat) for 3 days resulted in
down regulation of PGC1α and its target genes involved in
oxidative phosphorylation as compared to an isocaloric normal
fat diet (37 En% fat) [35]. In contrast, Turner et al. [36] reported
that consumption of a high-fat diet for 5–20 weeks in C57Bl/6J
mice induced insulin resistance despite an improved mitochondrial
oxidative capacity. Similarly, we found that an 8-week high-fat
dietary intervention in rats did not reduce ex vivo mitochondrial
function, as assessed by high-resolution respirometry in isolated
mitochondria. Moreover, the high-fat diet increased the protein
content of PGC1α [37], and the increase in PGC1α protein content
correlated with the protein content of several proteins of the
OXPHOS system, suggesting that in fact mitochondrial density was
increased after high-fat feeding. These improvements in mitochon-
drial metabolism were accompanied by marked accumulation of fat
in skeletal muscle [37]. In concordance, Hancock et al. [38] showed
that high-fat diets for 4–5 weeks increased mitochondrial density
via a stimulatory effect of fatty acid levels on PPARδ and PGC1α
protein content. Together, these data tend to suggest that high-fat
diets–although leading to insulin resistance in rodents–are not
accompanied by mitochondrial dysfunction. Rather they lead to
improved mitochondrial oxidative capacity, arguing against a role
for lipotoxicity in the development of diabetes-related mitochon-
drial dysfunction. However, the matter may be more complicated
than can initially be deduced from these data. For example, two
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drial function upon high-fat diets. Thus, Chanseaume et al. [39] fed
rats high-fat diets for 0, 3, 6, 9, 14, 20, or 40 days and determined
ex vivo mitochondrial activity in permeabilized muscle fibers. They
showed a transiently enhanced activity of the oxidative phosphor-
ylation after 14 days, but a significant decrease at day 40. Similarly,
Laurent et al. [40] showed in rats–using non-invasive imaging–that
ATP synthesis rates decreased by 50% within 24 h of raising the fat
content in the diet, but ATP synthesis returned to normal values
after 2–3 weeks on the HF diet. However, prolonged high-fat
feeding for longer than one month resulted in consistently lower
ATP synthesis rates by 30–50% accompanied by steadily augment-
ing IMCL levels [40]. In ZDF rats, we recently showed that in vivo
mitochondrial function (determined using non-invasive magnetic
resonance spectroscopy) declines similarly with age (from 6 to
18 weeks of age) in diabetic ZDF rats and insulin-sensitive fa/
+rats [41]. However, examination of intrinsic mitochondrial
function–ADP-stimulated and maximally uncoupled respiration in
isolated mitochondria–revealed that mitochondrial oxidative ca-
pacity also gradually decreased with age in the insulin-sensitive fa/
+rats. In contrast, however, mitochondrial respiration initially
improved in ZDF rats (from week 6 to week 12), when IMCL
accumulates and type 2 diabetes develops, but subsequently
showed a very rapid decline at an age of 18 weeks when overt
diabetes develops (Lenears et al., Obesity, in press). Finally,
Bonnard et al. [42] showed that 1 month of high-fat, high-sucrose
diet feeding was sufficient to induce glucose intolerance in mice,
without any evidence of mitochondrial dysfunction. However,
when the diet intervention was extended up to 16 weeks, they
observed altered mitochondrial biogenesis, structure, and function
in mouse muscle tissue, accompanied by the induction of a diabetic
state [42]. Interestingly, they showed that ROS production in
skeletal muscle of diet-induced diabetic mice was increased after
16 weeks of high-fat diet, but not after 4 weeks. Finally, in muscle
cells, they showed that glucose- or lipid-induced ROS production
resulted in mitochondrial alterations in vitro, and these effects were
blocked by antioxidant treatment. Interestingly, recent reports have
provided strong experimental evidence for ROS production in the
development of insulin resistance [43,44], suggesting that ROS
production may link muscular fat accumulation, mitochondrial
dysfunction and insulin resistance.
Taken together, these studies are overall consistent in showing
that: (1) rodents have the capacity to (initially) adapt mitochondrial
function to a high fat intake, (2) mitochondrial dysfunction only
occurs when high-fat diets are continued for a longer period and (3)
muscular fat accumulation and insulin resistance develop before
mitochondrial function deteriorates. Therefore, these data are
consistent with the hypothesis that mitochondrial dysfunction may
be a consequence rather than cause of muscular fat accumulation, and
that it develops when the protective mechanisms can–on the longer
term–no longer cope with high levels of muscular fatty acids, and as a
consequence lipotoxicity occurs. It should be noted however that such
lipid-induced mitochondrial dysfunction may lead to progressive
deterioration of muscular oxidative capacity and accumulation of lipid
intermediates in skeletal muscle, therefore not excluding that
mitochondrial dysfunction in fact does play a role in the etiology of
type 2 diabetes mellitus. Unfortunately, so far human studies that
manipulated muscular fat content and examined the effect on
mitochondrial function are lacking.
5. How can fatty acids lead to mitochondrial dysfunction
in muscle?
Next to the production of ATP, mitochondria are also the major
source of reactive oxygen species (ROS). Mitochondrial ROS can
rapidly react with mtDNA, protein and lipids, thereby leading tooxidative damage. Inmuscle cells fatty acids accumulate in the vicinity
of mitochondria and these fatty acids are very prone to ROS-induced
oxidative damage, resulting in the formation of lipid peroxides.
Especially accumulation of fatty acids in the inner mitochondrial
membrane of mitochondria, at the site where ROS are formed, would
be susceptible to peroxidation, subsequently inducing oxidative
damage to the mitochondrial machinery. To prevent mitochondrial
accumulation of fatty acids, their entry into mitochondria is regulated
by the enzyme CPT1 that serves as an inward transporter of oxidizable
fatty acids. However, this system cannot completely prevent the
diffusion of non-metabolizable fatty acid into the mitochondria.
Mitochondrial membranes consist of lipid bilayers and therefore
fatty acids can still ‘enter’ themitochondriamatrixmembrane via a so-
called ‘flip-flop’ mechanism over the membrane [45]. However, these
fatty acids cannot be oxidized due to the lack of acyl-CoA synthetase
inside the matrix and likely are incorporated in the inner mitochon-
drialmembrane,where theywould be vulnerable to oxidative damage.
This ‘passive diffusion’ is more likely to occur under conditions of high
fatty acid availability and low demand, as is often the case in the pre-
diabetic and diabetic state. This notion is supported by the observation
that skeletal muscle of obese insulin resistant subjects not only
contains a higher amount of intramyocellular lipid, but these lipids
also showed a higher degree of lipid peroxidation [46]. It is tempting to
suggest that these lipid peroxides lead to oxidative damage to
mitochondrial structures and contribute to the reducedmitochondrial
capacity observed in (pre-)diabetic patients [9]. Furthermore, this
suggestion is also in accordance with the finding of Bonnard et al. [42]
showing that high-fat diet induced mitochondrial dysfunction was
associated with increased ROS production.
Mitochondrial ROS production depends highly on the proton
gradient over the inner mitochondrial membrane (which drives
ATP synthesis) and a high proton gradient will increase ROS
production. One way to lower the proton gradient is by so-called
mitochondrial uncoupling, a process in which a reduction of the
proton gradient is not coupled to ATP production, but is due to
proton leakage. Since the relationship between ROS production and
the proton gradient is exponential, already a small decrease in
membrane potential (“mild uncoupling”) will reduce mitochondrial
ROS production considerably [47]. Therefore, at the expense of a
slight inefficiency in ATP production, mitochondrial uncoupling is a
powerful tool to control ROS formation and hence to preserve
mitochondrial functioning. Recently, this mitochondrial uncoupling
was linked to the maintenance of mitochondrial function in human
skeletal muscle during aging [48]. Thus, it has been observed that
during aging mitochondrial function decreased in the well-coupled
dorsal interosseus muscle while mitochondrial function was
maintained in mildly uncoupled mitochondria from aging tibialis
anterior muscle [48]. Although associative, these novel data suggest
that mitochondrial uncoupling might protect against (age-induced)
mitochondrial dysfunction.
As outlined above, especially fatty acids in the vicinity of
mitochondria would be prone to oxidative damage, leading to the
formation of lipid-peroxides. Interestingly, it is known for a long
time that fatty acids are capable of mitochondrial uncoupling [49],
but the reason why fatty acids do so is less clear. It can be
hypothesized that fatty-acid induced uncoupling lowers mitochon-
drial ROS production and thereby prevents mitochondrial lipotoxi-
city. Although, so far no direct evidence for this hypothesis has been
provided, we [50,51] and others [52,53] have previously suggested
that the muscle specific mitochondrial uncoupling protein-3 (UCP3)
may be involved in the protection of mitochondria against lipid-
induced mitochondrial damage. UCP3 may do so by exporting non-
metabolizable fatty acid anions or peroxides away from the
mitochondrial inner membrane before they are attacked by ROS,
or by directly lowering ROS production via mild mitochondrial
uncoupling. We have recently shown that mitochondrial ROS
Fig. 2. Mitochondrial uncoupling as a proposed protective mechanisms against
mitochondrial lipotoxicity: mitochondria produce reactive oxygen species (ROS) that
can attack mitochondrial fatty acids, leading to lipid peroxides. These peroxides are
highly reactive and could lead to damage to the mitochondrial machinery. However,
fatty acids can activate processes leading to mitochondrial uncoupling, thereby
reducing the proton gradient over the inner mitochondrial membrane. A lowering of
the proton gradient leads to a reduction of ROS production, providing a feedback
mechanism limiting mitochondrial lipotoxicity.
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isolated mitochondria, increased with age in wild type mice, but
this age-induced increase in mitochondrial ROS production was
blunted in mice overexpressing UCP3 [54]. In addition, we have
shown that the ablation of UCP3 was accompanied by higher levels
of muscular lipid peroxidation [55]. We have shown that UCP3 is
specifically upregulated in skeletal muscle when a dysbalance
between fatty acid delivery and fatty acid oxidative capacity exists
in muscle (for an extensive review, see: [51]). In short, UCP3 is
upregulated with high-fat diets [56,57], fasting [58], etomoxir
treatment (which inhibits the mitochondrial fatty acid oxidation)
[28,59] and lipid infusion [33], all conditions that are associated by
excessive lipid accumulation in skeletal muscle. On the other hand,
interventions improving fat oxidative capacity, like endurance
training [60,61] and weight loss [62], or lowering circulatory fatty
acids ([63,64]) are associated with a decrease in UCP3. Interestingly,
UCPs are activated by fatty acids and/or by peroxidation products of
fatty acids [53], and when activated UCPs may reduce mitochondrial
ROS production [53,54]. Therefore, it can be suggested that UCP3 is
involved in the protection against mitochondrial lipotoxicity by
lowering ROS production when activated by fatty acids (Fig. 2). In
that respect, it is of interest to note that only type 2 diabetic
patients and pre-diabetic subjects, who as outlined above are
characterized by excessive fat accumulation in skeletal muscle and
by mitochondrial dysfunction, have ∼50% lower UCP3 protein levels
[65,66] compared to obese control subjects who have similar IMCL
content but normal mitochondrial function. This suggests that fat
accumulation in skeletal muscle, combined with a defective
protection mechanisms and probably elevated ROS levels, may
lead to mitochondrial dysfunction.
6. Concluding remarks
In summary, although the evidence for mitochondrial dysfunc-
tion in type 2 diabetes mellitus is ample, there is so far no evidence
that this reduced mitochondrial function is causal in the develop-
ment of the disease. If anything, the results obtained so far tell us
that the relation between mitochondrial function and the develop-
ment of type 2 diabetes mellitus is not as simple as originally
assumed. The initial suggestion that a reduced mitochondrial
function precedes the accumulation of IMCL and insulin resistanceis not supported by all studies, as several studies show no
differences in IMCL despite reductions in mitochondrial function
in insulin-resistant and/or diabetic subjects [17,20]. Therefore, it
cannot be excluded that a reduced mitochondrial function may in
fact be the consequence rather than cause of the diabetic state, for
example caused by lipotoxic mechanisms [50]. The findings that
plasma fatty acid levels reduce the expression of PGC1α [33,34] are
negatively related to fasting muscular ATP synthesis [17], and
impair insulin-stimulated ATP synthesis [67], as well as the
observation of increased mitochondrial damage in type 2 diabetic
patients [9] support this hypothesis. Whether mitochondrial
dysfunction in type 2 diabetic patients and insulin-resistant subjects
is due to reduced protective mechanisms against mitochondrial
lipotoxicity deserves further study.
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